Method of treatment of asthma using antibodies to complement component C5
First Claim
Patent Images
1. A method of treating asthma in a subject comprising administering an anti-C5 antibody to a subject susceptible to or having asthma.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treatment of asthma with a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components such as, for example, a complement-inhibiting antibody. The compound can be administered prophylactically to prevent asthma attacks in known asthmatic individuals or as a therapeutic regimen during asthma attacks.
-
Citations
44 Claims
- 1. A method of treating asthma in a subject comprising administering an anti-C5 antibody to a subject susceptible to or having asthma.
-
2. A method of preventing asthma attacks comprising prophylactically administering an anti-C5 antibody to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms.
-
3. A method of reducing the severity of an asthma attack comprising administering an anti-C5 antibody to a subject having an asthma attack.
-
4. A method of reducing airway obstruction in a subject comprising administering an anti-C5 antibody to the subject.
-
5. A method of increasing air flow in a subject comprising administering an anti-C5 antibody to the subject.
-
6. A method of reducing bronchial spasms in a subject comprising administering an anti-C5 antibody to the subject.
-
7. A method of treating a chronic obstructive pulomonary disease in a subject comprising administering an anti-C5 antibody to the subject afflicted with a chronic obstructive pulomonary disease.
- 8. A method of reducing inflammation in a subject comprising administering an anti-C5 antibody to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms.
-
9. A method of treating a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms comprising administering an effective bronchial-dilating amount of an anti-C5 antibody.
-
20. A method for treating a subject having or susceptible to asthma comprising administering at least one member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL4 antibodies, anti-IL-5 antibodies, β
- 2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, β
2 adreno receptor agonists, PDE inhibitors, CD23 antagonists, IL 13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors in combination with an anti-C5 antibody.
- 2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, β
-
21. A method of treating asthma comprising administering an anti-C5 antibody to the lungs of a subject without substantially reducing systemic complement activity in the subject.
- 22. A method of treating asthma in a subject comprising administering a compound to the subject, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components, compounds which block the activity of one or more complement components and compounds which block the engagement of complement component receptors.
- 24. A method of reducing inflammation in a subject comprising administering a compound to the subject, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components, compounds which block the activity of one or more complement components and compounds which block the engagement of complement component receptors.
- 27. A method of treating a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms comprising administering a compound to the subject, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components, compounds which block the activity of one or more complement components and compounds which block the engagement of complement component receptors.
- 32. A method of preventing asthma attacks comprising prophylactically administering a compound to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components, compounds which block the activity of one or more complement components and compounds which block the engagement of complement component receptors.
- 34. A method of reducing the severity of an asthma attack comprising administering a compound to a subject having an asthma attack, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components, compounds which block the activity of one or more complement components and compounds which block the engagement of complement component receptors.
- 36. A method of reducing inflammation in the lungs of an asthma patient comprising the step of administering to a subject having or susceptible to asthma one or more compounds selected from the group consisting of soluble CR1, soluble LEX-CR1, soluble MCP, soluble DAF, soluble CD59, Factor H, cobra venom factor, FUT-175, complestatin, K76 COOH and antibodies directed against a compound selected from the group consisting of complement components C-1, C-2, C-3, C-4, C-5, C-6, C-7, C-8, C-9, Factor D, Factor B, Factor P, MBL, MASP-1, and MASP-2.
Specification